vs
Side-by-side financial comparison of CIMPRESS plc (CMPR) and EXACT SCIENCES CORP (EXAS). Click either name above to swap in a different company.
CIMPRESS plc is the larger business by last-quarter revenue ($1.0B vs $878.4M, roughly 1.2× EXACT SCIENCES CORP). CIMPRESS plc runs the higher net margin — 4.7% vs -9.8%, a 14.5% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 11.0%). CIMPRESS plc produced more free cash flow last quarter ($139.5M vs $120.4M).
Cimpress plc is an American Irish-domiciled multinational technology company that invests in and operates a wide variety of businesses that use mass customization to configure and produce small quantities of individually customized goods. Those products are sold to small businesses, graphic designers and consumers through a number of customer-facing brands that Cimpress operates.
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
CMPR vs EXAS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $878.4M |
| Net Profit | $49.3M | $-86.0M |
| Gross Margin | 46.8% | 70.1% |
| Operating Margin | 8.5% | -9.4% |
| Net Margin | 4.7% | -9.8% |
| Revenue YoY | 11.0% | 23.1% |
| Net Profit YoY | -19.2% | 90.1% |
| EPS (diluted) | $1.95 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $878.4M | ||
| Q3 25 | $863.3M | $850.7M | ||
| Q2 25 | — | $811.1M | ||
| Q1 25 | — | $706.8M | ||
| Q4 24 | — | $713.4M | ||
| Q3 24 | — | $708.7M | ||
| Q2 24 | — | $699.3M | ||
| Q1 24 | — | $637.5M |
| Q4 25 | $49.3M | $-86.0M | ||
| Q3 25 | $7.6M | $-19.6M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-101.2M | ||
| Q4 24 | — | $-864.6M | ||
| Q3 24 | — | $-38.2M | ||
| Q2 24 | — | $-15.8M | ||
| Q1 24 | — | $-110.2M |
| Q4 25 | 46.8% | 70.1% | ||
| Q3 25 | 46.7% | 68.6% | ||
| Q2 25 | — | 69.3% | ||
| Q1 25 | — | 70.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 69.4% | ||
| Q2 24 | — | 69.8% | ||
| Q1 24 | — | 70.0% |
| Q4 25 | 8.5% | -9.4% | ||
| Q3 25 | 5.7% | -3.0% | ||
| Q2 25 | — | -0.3% | ||
| Q1 25 | — | -13.6% | ||
| Q4 24 | — | -122.8% | ||
| Q3 24 | — | -5.6% | ||
| Q2 24 | — | -3.8% | ||
| Q1 24 | — | -16.7% |
| Q4 25 | 4.7% | -9.8% | ||
| Q3 25 | 0.9% | -2.3% | ||
| Q2 25 | — | -0.1% | ||
| Q1 25 | — | -14.3% | ||
| Q4 24 | — | -121.2% | ||
| Q3 24 | — | -5.4% | ||
| Q2 24 | — | -2.3% | ||
| Q1 24 | — | -17.3% |
| Q4 25 | $1.95 | $-0.45 | ||
| Q3 25 | $0.30 | $-0.10 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $-0.54 | ||
| Q4 24 | — | $-4.69 | ||
| Q3 24 | — | $-0.21 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $258.0M | $964.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-530.7M | $2.4B |
| Total Assets | $2.1B | $5.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $258.0M | $964.7M | ||
| Q3 25 | $200.5M | $1.0B | ||
| Q2 25 | — | $858.4M | ||
| Q1 25 | — | $786.2M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $946.8M | ||
| Q1 24 | — | $652.1M |
| Q4 25 | $-530.7M | $2.4B | ||
| Q3 25 | $-571.3M | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $3.1B |
| Q4 25 | $2.1B | $5.9B | ||
| Q3 25 | $2.0B | $5.9B | ||
| Q2 25 | — | $5.8B | ||
| Q1 25 | — | $5.7B | ||
| Q4 24 | — | $5.9B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | — | $6.7B | ||
| Q1 24 | — | $6.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $164.7M | $151.7M |
| Free Cash FlowOCF − Capex | $139.5M | $120.4M |
| FCF MarginFCF / Revenue | 13.4% | 13.7% |
| Capex IntensityCapex / Revenue | 2.4% | 3.6% |
| Cash ConversionOCF / Net Profit | 3.34× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $356.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $164.7M | $151.7M | ||
| Q3 25 | $25.1M | $219.9M | ||
| Q2 25 | — | $89.0M | ||
| Q1 25 | — | $30.8M | ||
| Q4 24 | — | $47.1M | ||
| Q3 24 | — | $138.7M | ||
| Q2 24 | — | $107.1M | ||
| Q1 24 | — | $-82.3M |
| Q4 25 | $139.5M | $120.4M | ||
| Q3 25 | $-1.3M | $190.0M | ||
| Q2 25 | — | $46.7M | ||
| Q1 25 | — | $-365.0K | ||
| Q4 24 | — | $10.7M | ||
| Q3 24 | — | $112.6M | ||
| Q2 24 | — | $71.2M | ||
| Q1 24 | — | $-120.0M |
| Q4 25 | 13.4% | 13.7% | ||
| Q3 25 | -0.1% | 22.3% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 10.2% | ||
| Q1 24 | — | -18.8% |
| Q4 25 | 2.4% | 3.6% | ||
| Q3 25 | 3.1% | 3.5% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 5.9% |
| Q4 25 | 3.34× | — | ||
| Q3 25 | 3.28× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMPR
| Vista | $532.8M | 51% |
| Print Brothers | $219.9M | 21% |
| National Pen | $150.9M | 14% |
| The Print Group | $115.2M | 11% |
| All Other Businesses | $67.2M | 6% |
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
